Ebola has affected more than 1,100 people in the Democratic Republic of Congo and Uganda, according to the African Union's health agency.Africa Centers for Disease Control and Prevention (CDC) Director General Jean Kaseya said there were 263 confirmed cases in both countries as of Saturday, with 43 confirmed deaths, The Financial Times reported.On Thursday, the Africa CDC said there had been 246 suspected deaths from the virus.Brazil Probes Two Suspected Ebola CasesMeanwhile, Brazil reported two suspected Ebola cases involving people who had travelled from affected countries.On May 31, local health authorities reported that a man from the Democratic Republic of the Congo with suspected Ebola infection in Brazil's São Paulo state tested positive for meningitis, Reuters reported. He had previously presented with a fever after a recent visit to an African country.The second case emerged in Rio de Janeiro state after a recent travel to Uganda, but the patient tested positive for malaria. In neither case does the diagnosis of other diseases rule out the possibility of Ebola, authorities said, adding that both cases remain under investigation.In a separate statement, Brazil's Health Ministry said the man in São Paulo has been intubated, and his condition is serious, Reuters reported.The latest outbreak of Ebola has been caused by the rare Bundibugyo virus, which has no approved treatment or vaccine. It is also known to kill about a third of those infected.5 Ebola Recoveries Offering a much-needed sign of hope, the World Health Organization (WHO) has reported five Ebola recoveries.Five patients have recovered from a rare type of Ebola, said WHO Director-General Tedros Adhanom Ghebreyesus during the opening of a new Ebola treatment centre in Bunia, the provincial capital of Ituri.“Four people will be discharged today, and there was one who was discharged the day before yesterday,” he said, adding that work is ongoing on “vaccines and treatments, but that doesn’t mean that people cannot recover from Ebola”.Bundibugyo Strain: Experimental Treatments, VaccinesAlso read: Ebola: Inside India’s RT-PCR Tests For The Bundibugyo Strain| Explained The WHO has also identified experimental treatments and vaccine candidates for the Bundibugyo strain. The global health agency convened several expert and advisory groups and recommended prioritizing treatment of Bundibugyo cases with: Mapp Biopharmaceutical's MBP134 Regeneron’s maftivimab Gilead Sciences’ antiviral remdesivir In addition, the WHO also advised evaluating combination therapy using a monoclonal antibody together with remdesivir. For post-exposure prophylaxis among contacts of confirmed and probable cases, the oral antiviral obeldesivir was identified as a priority candidate. The expert groups also identified the single-dose rVSV Bundibugyo vaccine, being developed by the International AIDS Vaccine Initiative (IAVI), as the most promising vaccine candidate. Another vaccine candidate, ChAdOx1 Bundibugyo — being developed by Oxford University and the Serum Institute of India — could potentially become available within 2–3 months for efficacy assessment through a clinical trial. However, additional animal data are still required to support and confirm further prioritization.The experts also reviewed the potential role of Merck's Ervebo, the only licensed Ebola vaccine currently available.